{"id":"W3202730600","doi":"10.1016/j.annonc.2021.08.1316","title":"906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cilag; Foundation Medicine; Genentech; Merck Sharp and Dohme; Julius Clinical; Ipsen; Daiichi Sankyo Europe; Servier; PharmaMar; European Society for Medical Oncology; Vifor Pharma; Basilea Pharmaceutica; Astellas Pharma; Eisai; Springworks Therapeutics; Celldex Therapeutics; MacroGenics; Pfizer; Incyte; Moderna; Shionogi; Actuate Therapeutics; BeiGene; Mirati Therapeutics; Agios Pharmaceuticals; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Karyopharm Therapeutics; F. Hoffmann-La Roche; Bayer HealthCare; Sanofi; GlaxoSmithKline; Amgen; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cetuximab; Head and neck; Oncology; Head and neck squamous-cell carcinoma; Basal cell; Head and neck cancer; Internal medicine; Radiation therapy; Cancer; Surgery; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003328587,0.0003581156,0.0008774904,0.0002236182,0.0001792859,0.0002820327,0.0002672702,0.0002530664,0.001079253],"category_scores_gemma":[0.0003133615,0.0001279036,0.0004507696,0.0002670792,0.0001316638,0.0002278329,0.0001695615,0.0007507488,0.0001978742],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004871424,"about_ca_system_score_gemma":0.0004572035,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00102388,"about_ca_topic_score_gemma":0.004859167,"domain_scores_codex":[0.9998865,0.00002851274,0.00001014851,0.00001888373,0.00002503058,0.0000308581],"domain_scores_gemma":[0.999923,0.00001445178,0.00001491959,0.000005356222,0.000006456291,0.00003589677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1458688,0.004882216,0.08534174,0.001421902,0.003126,0.003594401,0.0003845555,0.006374178,0.08708772,0.0006100021,0.007688401,0.6536201],"study_design_scores_gemma":[0.04935167,0.2209166,0.6045058,0.0003948746,0.007234296,0.01565439,0.0007093226,0.01739446,0.03706843,0.00124494,0.04536462,0.0001604402],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871017,0.008881105,0.0002135088,0.0004799535,0.0001230448,0.00009726889,0.000162647,0.0000396031,0.002901132],"genre_scores_gemma":[0.9955669,0.002577587,0.0002471948,0.0001974835,0.00004709905,0.00003164144,0.0002679599,0.000004572004,0.001059503],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001079253,"threshold_uncertainty_score":0.003610492,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04584884768537117,"score_gpt":0.3325130936566644,"score_spread":0.2866642459712933,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}